Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

NCT02959749 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT02959749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Lead sponsor
Qingdao Central Hospital
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2015
Completion date
December 31, 2017
Enrollment
147 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

progression free survival